m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00567
 [1], [2], [3]
m6A modification pri-miR-143 pri-miR-143 VIRMA Methylation : m6A sites Indirect Enhancement RNA modification STAT3 STAT3 ADAR Methylation : modification sites
m6A Modification:
m6A Regulator Protein virilizer homolog (VIRMA) WRITER
 Regulator Info 
m6A Target pri-miR-143
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target Signal transducer and activator of transcription 3 (STAT3) View Details
Crosstalk Relationship m6A  →  A-to-I Enhancement
Crosstalk Mechanism m6A modification indirectly impacts RNA modification through downstream signaling pathways
Crosstalk Summary VIRMA interacts with pri-miR-143, increasing its m6A level and promoting its physical interaction with Signal transducer and activator of transcription 3 (STAT3), which was regulated by ADAR1-mediated A-to-I modification.
In-vitro Model
LB
 N.A. Homo sapiens CVCL_E751
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Signal transducer and activator of transcription 3 (STAT3) 74 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Acitretin Approved [4]
Synonyms
Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5284513
TTD: D05QDC
DrugBank: DB00459
 Compound Name Napabucasin Phase 3 [5]
Synonyms
83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 1900 nM
External Link
CID: 10331844
TTD: D01IGZ
DrugBank: DB12155
 Compound Name Golotimod Phase 2 [6]
Synonyms
229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6992140
TTD: D02MRN
DrugBank: DB05475
 Compound Name Atiprimod Phase 1/2 [7]
Synonyms
Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 129869
TTD: D0D9LJ
DrugBank: DB05513
 Compound Name OPB-31121 Phase 1/2 [8]
MOA Inhibitor
External Link
TTD: D0E7IM
 Compound Name IMX-110 Phase 1/2 [5]
MOA Inhibitor
External Link
TTD: D0H7DM
 Compound Name GLG-801 Phase 1/2 [5]
MOA Inhibitor
External Link
TTD: D0P7IL
 Compound Name WP-1066 Phase 1/2 [5]
Synonyms
WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11210478
TTD: D0IV4C
DrugBank: DB12679
 Compound Name NT219 Phase 1/2 [9]
Synonyms
UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135914977
TTD: DUI59O
 Compound Name OPB-51602 Phase 1 [10]
MOA Inhibitor
External Link
TTD: D01FFC
 Compound Name TAK-114 Phase 1 [11]
MOA Modulator
External Link
TTD: D01RCM
 Compound Name WP1220 Phase 1 [12]
Synonyms
mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44554865
TTD: D3U8YR
 Compound Name DSP-0337 Phase 1 [13]
MOA Inhibitor
External Link
TTD: DLJN17
 Compound Name OPB-111077 Phase 1 [14]
MOA Inhibitor
External Link
TTD: DN81JB
 Compound Name Quinoline carboxamide derivative 2 Patented [15]
Synonyms
PMID26394986-Compound-29
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 67206397
TTD: D00FUZ
 Compound Name Peptidomimetic analog 3 Patented [15]
Synonyms
PMID26394986-Compound-5
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24772856
TTD: D02CJU
 Compound Name PMID26394986-Compound-11 Patented [15]
MOA Inhibitor
External Link
CID: 341
TTD: D02ILH
 Compound Name Flavonoid derivative 5 Patented [15]
Synonyms
PMID26394986-Compound-49
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D02KDA
 Compound Name Salicylic acid derivative 6 Patented [15]
Synonyms
PMID26394986-Compound-18
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 10000 nM
External Link
CID: 72550504
TTD: D03ARS
 Compound Name Gold-complexed thiosaccharide derivative 2 Patented [15]
Synonyms
PMID26394986-Compound-67
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 56946870
TTD: D03HEP
 Compound Name Peptidomimetic analog 1 Patented [15]
Synonyms
PMID26394986-Compound-3
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 125 nM
External Link
TTD: D03VMP
 Compound Name Quinoline carboxamide derivative 1 Patented [15]
Synonyms
PMID26394986-Compound-28
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 74000 nM
External Link
CID: 4253236
TTD: D03XAK
 Compound Name Salicylic acid derivative 4 Patented [15]
Synonyms
PMID26394986-Compound-16
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72545583
TTD: D04ANB
 Compound Name PMID26394986-Compound-12 Patented [15]
MOA Inhibitor
External Link
CID: 237973
TTD: D04GVY
 Compound Name PMID26394986-Compound-21 Patented [15]
MOA Inhibitor
Activity IC50 = 15000 nM
External Link
CID: 73672447
TTD: D06RBL
 Compound Name Salicylic acid derivative 5 Patented [15]
Synonyms
PMID26394986-Compound-17
    Click to Show/Hide
MOA Inhibitor
Activity Kd = 300 nM
External Link
CID: 72188643
TTD: D08EID
 Compound Name PMID26394986-Compound-20 Patented [15]
MOA Inhibitor
Activity IC50 = 45000 nM
External Link
CID: 76336555
TTD: D08ETA
 Compound Name PMID26394986-Compound-43 Patented [15]
MOA Inhibitor
External Link
CID: 46911017
TTD: D08SEP
 Compound Name PMID26394986-Compound-50 Patented [15]
MOA Inhibitor
External Link
CID: 9881541
TTD: D09BOL
 Compound Name PMID26394986-Compound-44 Patented [15]
MOA Inhibitor
External Link
CID: 65064
TTD: D09CKU
DrugBank: DB12116
 Compound Name PMID26394986-Compound-51 Patented [15]
MOA Inhibitor
External Link
CID: 118707758
TTD: D09SYX
 Compound Name Salicylic acid derivative 3 Patented [15]
Synonyms
PMID26394986-Compound-14a
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 12800 nM
External Link
CID: 73333953
TTD: D09ZCV
 Compound Name Quinoline carboxamide derivative 3 Patented [15]
Synonyms
PMID26394986-Compound-30
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 67204713
TTD: D0D8RR
 Compound Name Pyrazole derivative 62 Patented [15]
Synonyms
PMID26394986-Compound-23
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72543768
TTD: D0DC3S
 Compound Name Pyrazole derivative 63 Patented [15]
Synonyms
PMID26394986-Compound-24
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72705159
TTD: D0ET3L
 Compound Name Flavonoid derivative 3 Patented [15]
Synonyms
PMID26394986-Compound-47
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5281612
TTD: D0EV5U
DrugBank: DB11259
 Compound Name Peptide analog 7 Patented [15]
Synonyms
PMID26394986-Compound-1
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0EW9W
 Compound Name Salicylic acid derivative 1 Patented [15]
Synonyms
PMID26394986-Compound-13a
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2800 nM
External Link
CID: 68075823
TTD: D0EX9O
 Compound Name Gold-complexed thiosaccharide derivative 1 Patented [15]
Synonyms
PMID26394986-Compound-66
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0FH4G
 Compound Name Gold-complexed thiosaccharide derivative 3 Patented [15]
Synonyms
PMID26394986-Compound-68
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0J1US
 Compound Name PMID26394986-Compound-22 Patented [15]
MOA Inhibitor
External Link
CID: 2662
TTD: D0KP0U
DrugBank: DB00482
 Compound Name Pyrazole derivative 65 Patented [15]
Synonyms
PMID26394986-Compound-26
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72705348
TTD: D0M5AR
 Compound Name Pyrazole derivative 64 Patented [15]
Synonyms
PMID26394986-Compound-25
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72705347
TTD: D0M8OV
 Compound Name PMID26394986-Compound-42 Patented [15]
MOA Inhibitor
External Link
CID: 9799188
TTD: D0MA8T
 Compound Name Peptidomimetic analog 2 Patented [15]
Synonyms
PMID26394986-Compound-4
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 17 nM
External Link
TTD: D0QR1I
 Compound Name Pyrazole derivative 66 Patented [15]
Synonyms
PMID26394986-Compound-27
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0S0UL
 Compound Name PMID26394986-Compound-52 Patented [15]
MOA Inhibitor
External Link
TTD: D0T1GB
 Compound Name Salicylic acid derivative 2 Patented [15]
Synonyms
PMID26394986-Compound-14
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 19000 nM
External Link
CID: 53388144
TTD: D0U7LL
 Compound Name Salicylic acid derivative 7 Patented [15]
Synonyms
PMID26394986-Compound-19
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 10000 nM
External Link
CID: 72545832
TTD: D0V3PA
 Compound Name PMID26394986-Compound-53 Patented [15]
MOA Inhibitor
External Link
CID: 25226944
TTD: D0V7HS
 Compound Name Flavonoid derivative 1 Patented [15]
Synonyms
PMID26394986-Compound-45
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5280445
TTD: D0V7NH
DrugBank: DB15584
 Compound Name PMID26394986-Compound-54 Patented [15]
MOA Inhibitor
External Link
CID: 25226945
TTD: D0WW1Z
 Compound Name Peptidomimetic analog 4 Patented [15]
Synonyms
PMID26394986-Compound-6
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0X6QQ
 Compound Name PMID26394986-Compound-13 Patented [15]
MOA Inhibitor
Activity IC50 = 35000 nM
External Link
CID: 24767791
TTD: D0Y0OQ
 Compound Name Tri-substituted purine derivative 1 Patented [15]
Synonyms
PMID26394986-Compound-9
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 71770709
TTD: D0Y2PO
 Compound Name Flavonoid derivative 4 Patented [15]
Synonyms
PMID26394986-Compound-48
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5280343
TTD: D0Y3DN
DrugBank: DB04216
 Compound Name Flavonoid derivative 2 Patented [15]
Synonyms
PMID26394986-Compound-46
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0Z8BD
 Compound Name PMID26394986-Compound-Figure16 Patented [15]
MOA Inhibitor
Activity IC50 < 150 nM
External Link
TTD: D0ZQ8T
 Compound Name PMID26394986-Compound-Figure17 Patented [15]
MOA Inhibitor
External Link
TTD: D0ZS8Q
 Compound Name Oxazole derivative 1 Patented [15]
Synonyms
PMID26394986-Compound-8
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 79000 nM
External Link
CID: 24768190
TTD: D0EZ6V
 Compound Name Curcumin analog 2 Patented [15]
Synonyms
PMID26394986-Compound-33
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 68019246
TTD: D0IC8O
 Compound Name Curcumin analog 1 Patented [15]
Synonyms
PMID26394986-Compound-32
    Click to Show/Hide
MOA Inhibitor
Activity Kd = 172 nM
External Link
CID: 11487078
TTD: D0WD1Z
 Compound Name Peptidomimetic analog 5 Patented [15]
Synonyms
PMID26394986-Compound-7
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 310000 nM
External Link
CID: 9870708
TTD: D0XQ3F
 Compound Name Platinum IV complexe 1 Patented [15]
Synonyms
PMID26394986-Compound-69
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1400 nM
External Link
TTD: D01BVU
 Compound Name PMID26394986-Compound-10 Patented [15]
MOA Inhibitor
Activity IC50 = 86000 nM
External Link
CID: 252682
TTD: D0TU0X
 Compound Name GNF-PF-1399 Investigative [16]
Synonyms
GNF-PF-2708; GNF-PF-4643
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 107464
TTD: D06PZK
 Compound Name ISIS-STAT3 Phase 1/2 [17]
External Link
TTD: D0B4MK
 Compound Name C188-9 Phase 1 [17]
Synonyms
QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9
    Click to Show/Hide
External Link
CID: 1324494
TTD: D09CLC
 Compound Name ISIS 113187 Investigative [17]
External Link
TTD: D03MRO
 Compound Name ISIS 113176 Investigative [17]
External Link
TTD: D07XRC
 Compound Name ISIS 113209 Investigative [17]
External Link
TTD: D09YBP
 Compound Name ISIS 113210 Investigative [17]
External Link
TTD: D0E3ZU
 Compound Name ISIS 17148 Investigative [17]
External Link
TTD: D0O3DZ
 Compound Name ISIS 17152 Investigative [17]
External Link
TTD: D0W2FY
References
Ref 1 Alternative Splicing of STAT3 Is Affected by RNA Editing. DNA Cell Biol. 2017 May;36(5):367-376. doi: 10.1089/dna.2016.3575. Epub 2017 Mar 9.
Ref 2 KIAA1429 and ALKBH5 Oppositely Influence Aortic Dissection Progression via Regulating the Maturation of Pri-miR-143-3p in an m6A-Dependent Manner. Front Cell Dev Biol. 2021 Aug 19;9:668377. doi: 10.3389/fcell.2021.668377. eCollection 2021.
Ref 3 CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Ralpha1 and STAT3. Biochem Genet. 2021 Apr;59(2):531-546. doi: 10.1007/s10528-020-10003-0. Epub 2020 Nov 15.
Ref 4 [Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells]. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 National Cancer Institute Drug Dictionary (drug id 617379).
Ref 7 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 8 OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52. doi: 10.1016/j.canlet.2013.02.010. Epub 2013 Feb 10.
Ref 9 Clinical pipeline report, company report or official report of Purple Biotech.
Ref 10 Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005. doi: 10.1093/annonc/mdv026. Epub 2015 Jan 21.
Ref 11 Clinical pipeline report, company report or official report of Gastroenterology.
Ref 12 Clinical pipeline report, company report or official report of Moleculin Biotech.
Ref 13 Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289. doi: 10.1186/s13046-019-1289-6.
Ref 14 Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2019 Apr;51(2):510-518. doi: 10.4143/crt.2018.226. Epub 2018 Jun 13.
Ref 15 A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
Ref 16 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
Ref 17 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.